2016
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. New England Journal Of Medicine 2016, 375: 209-219. PMID: 27264120, PMCID: PMC5024713, DOI: 10.1056/nejmoa1604700.Peer-Reviewed Original ResearchConceptsContralateral breast cancerDisease-free survivalAromatase inhibitorsBreast cancerOverall survivalDisease-free survival ratesPositive early breast cancerAdjuvant aromatase inhibitorsNew-onset osteoporosisPlacebo-controlled trialPrimary end pointEarly breast cancerAnnual incidence rateTreatment of choiceBreast cancer recurrenceExtension of treatmentQuality of lifeBone painLetrozole groupAdjuvant therapyPlacebo groupPostmenopausal womenDisease recurrenceIncidence rateLower incidence
2012
Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT).
Winer E, Tolaney S, Nechushtan H, Berger R, Kurzrock R, Ron I, Schoffski P, Awada A, Yasenchak C, Burris H, Ramies D, Rafferty T, Shen X. Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT). Journal Of Clinical Oncology 2012, 30: 535-535. DOI: 10.1200/jco.2012.30.15_suppl.535.Peer-Reviewed Original ResearchProgression-free survivalMetastatic breast cancerBone scanTumor regressionWk 12Common grade 3/4 AEsMedian progression-free survivalPost-baseline tumour assessmentActivity of cabozantinibGrade 5 AEsMedian age 56Median prior linesObjective response rateObjective tumor regressionStudy days 1Breast cancer developmentDysregulation of METBone painEligible patientsEvaluable ptsMeasurable diseasePrior anthracyclineSerum NTxImproved painPrimary endpoint